NCI Drug Dictionary
The search textbox has an autosuggest feature. When you enter three or more characters, a list of up to 10 suggestions will popup under the textbox. Use the arrow keys to move through the suggestions. To select a suggestion, hit the enter key. Using the escape key closes the listbox and puts you back at the textbox. The radio buttons allow you to toggle between having all search items start with or contain the text you entered in the search box.
carbon C 14-labeled ixazomib
A radioconjugate comprised of the orally-available, reversible 20S proteasome inhibitor ixazomib that is labeled with the isotope carbon C 14. Upon administration, the ixazomib moiety hydrolyzes and generates its active form, MLN2238, which inhibits the activity of the 20S catalytic core subunit of the proteasome. This blocks the targeted proteolysis normally performed by the proteasome, which results in an accumulation of unwanted or misfolded proteins. The accumulation of protein may disrupt various cell signaling pathways, induce apoptosis, and inhibit tumor growth. In addition, this agent targets tumor suppressor microRNA-33b (miR-33b). Labeling with the radioactive tracer carbon C 14 allows for evaluation of ixazomib’s absorption, distribution, metabolism and excretion (ADME). Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
|Chemical structure:||[14C]--1, 4-(R,S)-(carboxymethyl)-2-((R)-1-(2-(2,5-dichlorobenzamido)acetamido)-3-methylbutyl)-6-oxo-1,3,2-dioxaborinane-4-carboxylic acid|